v3.21.1
Revenue (Tables)
3 Months Ended
Apr. 02, 2021
Revenue [Abstract]  
Schedule of Revenue by Major Customers by Reporting Segments
The Company’s Fabrication Technology segment formulates, develops, manufactures and supplies consumable products and equipment. Substantially all revenue from the Fabrication Technology business is recognized at a point in time. The Company disaggregates its Fabrication Technology revenue into the following product groups:
Three Months Ended
April 2, 2021April 3, 2020
(In thousands)
Equipment$173,750 $156,800 
Consumables394,378 368,737 
Total$568,128 $525,537 

Contracts with customers in the consumables product grouping generally have a shorter fulfillment period than equipment contracts.
The Company’s Medical Technology segment provides products and services spanning the full continuum of patient care, from injury prevention to rehabilitation. While the Company’s Medical Technology sales are primarily derived from three sales channels including dealers and distributors, insurance, and direct to consumers and hospitals, substantially all its revenue is recognized at a point in time.

The Company disaggregates its Medical Technology revenue into the following product groups:
Three Months Ended
April 2, 2021April 3, 2020
(In thousands)
Prevention & Recovery(1)
$235,238 $223,785 
Reconstructive75,845 67,034 
Total$311,083 $290,819 
(1) For the periods presented, the Prevention & Recovery product group includes bone growth stimulation products, which were previously classified as part of the Reconstructive product group.
Financing Receivable, Allowance for Credit Loss
A summary of the activity in the Company’s allowance for credit losses included within Trade receivables in the Condensed Consolidated Balance Sheets is as follows:
Three Months Ended April 2, 2021
Balance at
Beginning
of Period
Charged to Expense, netWrite-Offs and DeductionsForeign
Currency
Translation
Balance at
End of
Period
(In thousands)
Allowance for credit losses$37,666 $239 $(1,062)$(1,283)$35,560